Wu Xiaofei, Wang Ziyang, Liu Shupeng, Wang Hongyun
Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.
Drug Des Devel Ther. 2025 Apr 22;19:3077-3101. doi: 10.2147/DDDT.S501143. eCollection 2025.
China is undergoing a pronounced shift towards an aging society, wherein the elderly constitute a prominent demographic relying significantly on medications. The imperative of administering rational medication to the elderly has gained considerable importance and warrants focused attention. The availability of pharmacokinetic (PK) data specific to the elderly is paramount for supporting informed medication practices. Unfortunately, studies addressing PK in the elderly are both infrequent and intricate, contributing to a lack of crucial data essential for tailoring personalized and rational medication approaches.
This study aimed to address this deficiency by employing the Physiologically Based Pharmacokinetic (PBPK) model, with the goal of supplying critical data to support rational medication strategies for the elderly. Additionally, we extended the application of PBPK models to Therapeutic Drug Monitoring (TDM) through the examination of four neuropsychiatric drugs.
The PBPK models for 50 drugs in young and middle-aged Chinese adults were validated using clinical trial data. Simulated concentration-time curves closely matched the observed data, with C and AUC ratios within 0.5-2.0. For Chinese elderly, PBPK models for four drugs (ticagrelor, rivaroxaban, alprazolam, midazolam) showed strong agreement with observed data. Comparing PK profiles of 50 drugs, no significant differences were found between elderly and younger adults. Dosage recommendations for four neuropsychiatric drugs in the elderly were provided based on simulation results, ensuring therapeutic effectiveness and safety.
In conclusion, PBPK models for 50 commonly prescribed drugs within the Chinese elderly population were developed, tackling general data gaps associated with these specific medications. Medication plans were developed specifically tailored for the elderly population, presenting an alternative methodology and perspective for the implementation of individualized and rational medication practices.
中国正经历向老龄化社会的显著转变,老年人构成了显著依赖药物的主要人口群体。对老年人进行合理用药的必要性已变得相当重要,值得重点关注。针对老年人的药代动力学(PK)数据对于支持明智的用药实践至关重要。不幸的是,针对老年人PK的研究既不常见又复杂,导致缺乏为制定个性化和合理用药方法所必需的关键数据。
本研究旨在通过采用基于生理的药代动力学(PBPK)模型来解决这一不足,目标是提供关键数据以支持老年人的合理用药策略。此外,我们通过对四种神经精神药物的研究,将PBPK模型的应用扩展到治疗药物监测(TDM)。
使用临床试验数据对中国中青年50种药物的PBPK模型进行了验证。模拟的浓度-时间曲线与观察数据密切匹配,C和AUC比值在0.5-2.0范围内。对于中国老年人,四种药物(替格瑞洛、利伐沙班、阿普唑仑、咪达唑仑)的PBPK模型与观察数据显示出高度一致性。比较50种药物的PK特征,老年人和年轻人之间未发现显著差异。根据模拟结果给出了老年人四种神经精神药物的剂量建议,确保了治疗效果和安全性。
总之,针对中国老年人群体中50种常用处方药建立了PBPK模型,解决了与这些特定药物相关的一般数据空白。制定了专门针对老年人群体的用药计划,为实施个体化和合理用药实践提供了一种替代方法和视角。